Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun 27;16(6):e63332.
doi: 10.7759/cureus.63332. eCollection 2024 Jun.

Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report

Yoan E Rodriguez  1 , Maham Shahid  2 , Natalia Badillo  2 , Augusto Villegas  3 , Nilmarie Guzman  2
Affiliations
Case Reports

Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report

Yoan E Rodriguez et al. Cureus. .

Abstract

Adenoid cystic carcinoma (ACC) is an uncommon and aggressive head and neck cancer mainly affecting minor salivary glands. It affects more women than men in their 60s and 70s. The tumor is typically locally aggressive and has a high rate of distant metastatic disease. This report unveils a potential avenue for targeted therapy for the management of metastatic disease: a patient with ACC who harbored a specific fibroblast growth factor receptor 2 (FGFR-2) mutation and responded significantly to a novel FGFR-2 inhibitor. This finding could pave the way for personalized treatment options for ACC patients with similar genetic alterations. Nevertheless, the use of futibatinib requires further investigation to optimize treatment protocols, including exploring combination therapies, identifying predictive biomarkers for treatment response, and developing strategies to overcome potential resistance.

Keywords: adenoid cystic carcinoma (acc); fibroblast growth factor inhibitor; fibroblast growth factor receptor (fgfr); futibatinib; salivary gland tumor.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Pre-treatment positron emission tomography-computed tomography (PET-CT) scan of the head and neck
Images A and B display coronal views, whereas images C and D show axial views of the PET-CT scan. This scan reveals a region of increased fluorodeoxyglucose (FDG) uptake along the left subcutaneous scalp, which is thickened and measures 6.3 cm in the anteroposterior dimension. The maximum standardized uptake value (SUV) noted is 8.7. There is no clear evidence of FDG avid adenopathy.
Figure 2
Figure 2. Post-treatment positron emission tomography-computed tomography (PET-CT) scan of the head and neck
Images A and B display coronal views, whereas images C and D present axial views of a follow-up PET-CT scan. The scan indicates a significant reduction in soft tissue thickening in the left subcutaneous scalp, now showing an essentially physiological appearance on the CT images. The intensity reveals a maximum SUV of up to 3.7, in contrast to the previous maximum SUV of 8.7. Additionally, there is no evidence of fluorodeoxyglucose (FDG) avid adenopathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Adenoid cystic carcinoma of salivary glands: a ten-year review and an assessment of the current management, surgery, radiotherapy, and chemotherapy. Saleh E, Ukwas A. Int J Otolaryngol. 2023;2023:7401458. - PMC - PubMed
    1. Adenoid cystic carcinoma of the head and neck - treatment strategies of a highly malignant tumor with variable localizations. Dudde F, Henkel KO, Barbarewicz F. Oncoscience. 2023;10:27–29. - PMC - PubMed
    1. Clinical experience of 23 cases of adenoid cystic carcinoma of the external auditory canal. Jiang X, Jia L, Zhang X, Zhong C, Tang F, Chen X, Yuan W. Oncol Lett. 2020;20:144. - PMC - PubMed
    1. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. Nat Rev Clin Oncol. 2024;21:312–319. - PubMed
    1. Fibroblast growth factor receptors as treatment targets in clinical oncology. Katoh M. Nat Rev Clin Oncol. 2019;16:105–122. - PubMed

Publication types

LinkOut - more resources